138 related articles for article (PubMed ID: 30950223)
1. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans-Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise.
Cloak K; Jameson MG; Paneghel A; Wiltshire K; Kneebone A; Pearse M; Sidhom M; Tang C; Fraser-Browne C; Holloway LC; Haworth A
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):390-398. PubMed ID: 30950223
[TBL] [Abstract][Full Text] [Related]
2. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial.
Jameson MG; McNamara J; Bailey M; Metcalfe PE; Holloway LC; Foo K; Do V; Mileshkin L; Creutzberg CL; Khaw P
J Med Imaging Radiat Oncol; 2016 Aug; 60(4):554-9. PubMed ID: 27059658
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy.
Trada Y; Kneebone A; Paneghel A; Pearse M; Sidhom M; Tang C; Wiltshire K; Haworth A; Fraser-Browne C; Martin J
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1045-51. PubMed ID: 26475066
[TBL] [Abstract][Full Text] [Related]
4. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the relationship between contouring variability and modelled treatment outcome for prostate bed radiotherapy.
Le Bao V; Haworth A; Dowling J; Walker A; Arumugam S; Jameson M; Chlap P; Wiltshire K; Keats S; Cloak K; Sidhom M; Kneebone A; Holloway L
Phys Med Biol; 2024 Apr; 69(8):. PubMed ID: 38471173
[No Abstract] [Full Text] [Related]
6. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
[TBL] [Abstract][Full Text] [Related]
7. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
8. Prospective MRI-based imaging study to assess feasibility of proton therapy for post-prostatectomy radiation.
Swisher-McClure S; Yin L; Rosen M; Batra S; Berman AT; Both S; Vapiwala N
Acta Oncol; 2016 Jul; 55(7):828-33. PubMed ID: 27145164
[TBL] [Abstract][Full Text] [Related]
9. Anatomic variations due to radical prostatectomy. Impact on target volume definition and dose-volume parameters of rectum and bladder.
Sanguineti G; Castellone P; Foppiano F; Franzone P; Marcenaro M; Tognoni P; Bolognesi A; Ceresoli GL; Fiorino C
Strahlenther Onkol; 2004 Sep; 180(9):563-72. PubMed ID: 15378187
[TBL] [Abstract][Full Text] [Related]
10. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
[TBL] [Abstract][Full Text] [Related]
12. Assessing the effect of a contouring protocol on postprostatectomy radiotherapy clinical target volumes and interphysician variation.
Mitchell DM; Perry L; Smith S; Elliott T; Wylie JP; Cowan RA; Livsey JE; Logue JP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):990-3. PubMed ID: 19345515
[TBL] [Abstract][Full Text] [Related]
13. Impact of
Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
[TBL] [Abstract][Full Text] [Related]
14. The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02).
Foppiano F; Fiorino C; Frezza G; Greco C; Valdagni R;
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):573-9. PubMed ID: 12957271
[TBL] [Abstract][Full Text] [Related]
15. Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy.
Liu F; Ahunbay E; Lawton C; Li XA
Med Phys; 2014 Mar; 41(3):031710. PubMed ID: 24593714
[TBL] [Abstract][Full Text] [Related]
16. Proposal of a post-prostatectomy clinical target volume based on pre-operative MRI: volumetric and dosimetric comparison to the RTOG guidelines.
Croke J; Maclean J; Nyiri B; Li Y; Malone K; Avruch L; Kayser C; Malone S
Radiat Oncol; 2014 Dec; 9():303. PubMed ID: 25534278
[TBL] [Abstract][Full Text] [Related]
17. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
[TBL] [Abstract][Full Text] [Related]
18. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
[TBL] [Abstract][Full Text] [Related]
19. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer.
Salembier C; Villeirs G; De Bari B; Hoskin P; Pieters BR; Van Vulpen M; Khoo V; Henry A; Bossi A; De Meerleer G; Fonteyne V
Radiother Oncol; 2018 Apr; 127(1):49-61. PubMed ID: 29496279
[TBL] [Abstract][Full Text] [Related]
20. Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability.
Fiorino C; Vavassori V; Sanguineti G; Bianchi C; Cattaneo GM; Piazzolla A; Cozzarini C
Radiother Oncol; 2002 Jun; 63(3):249-55. PubMed ID: 12142088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
